Bone events halt OncoMed early 'Wnt' studies; shares drop
This article was originally published in Scrip
Executive Summary
Shares of OncoMed Pharmaceuticals plummeted 25% on 13 June after the cancer drug developer revealed it had voluntarily stopped patient enrollment and dosing in its ongoing Phase I trials testing two Wnt pathway inhibitors – vantictumab (anti-Fzd7, OMP-18R5) and Fzd8-Fc (OMP-54F28) – following reports of mild-to-moderate adverse bone-related events.
You may also be interested in...
OncoMed Absorbs Double Dose Of Bad News With Trial Failure, Two Options Declined
The California biotech's Phase II pancreatic cancer candidate demcizumab failed to show benefit versus placebo for progression-free or overall survival. Meanwhile, Bayer decided not to exercise its options on a pair of Wnt pathway candidates under a 2010 collaboration with OncoMed.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.